JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Clenbuterol is a research compound studied in cell-based assay formats for its selective beta-2 adrenergic receptor (beta-2 AR) agonist properties and downstream signaling pathway activation. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and metabolic pathway engagement in defined cell model systems under controlled laboratory conditions.
Clenbuterol demonstrates high selectivity for the beta-2 adrenergic receptor subtype, exhibiting nanomolar binding affinity in radioligand displacement assays. Competitive binding studies using [³H]-CGP-12177 reveal Ki values ranging from 0.2-2.1 nM across various mammalian cell expression systems. The compound's structural phenethylamine backbone confers specificity through interactions with key amino acid residues in the beta-2 AR transmembrane domains, particularly Asp113 and Ser203/204/207.
Upon beta-2 AR binding, clenbuterol activates the Gs-protein signaling cascade, leading to adenylyl cyclase stimulation and intracellular cyclic adenosine monophosphate (cAMP) accumulation. In vitro cAMP accumulation assays demonstrate dose-dependent responses with EC50 values typically ranging from 0.1-10 nM in transfected cell lines. The compound exhibits full agonist properties, achieving maximum cAMP responses comparable to isoproterenol in functional assays.
Elevated cAMP levels trigger protein kinase A (PKA) activation through dissociation of regulatory and catalytic subunits. PKA-mediated phosphorylation events serve as key downstream effectors, with particular relevance to phosphorylation of cAMP response element-binding protein (CREB) and hormone-sensitive lipase. In vitro kinase assays demonstrate time-dependent PKA activation following clenbuterol exposure in adipocyte cell models.
Clenbuterol exposure in cell culture systems activates AMP-activated protein kinase (AMPK) through mechanisms involving increased AMP:ATP ratios and calcium-dependent pathways. AMPK activation leads to phosphorylation of acetyl-CoA carboxylase (ACC) at Ser79, effectively inhibiting fatty acid synthesis. Western blot analysis in 3T3-L1 adipocytes shows significant ACC phosphorylation within 30-60 minutes of clenbuterol treatment at micromolar concentrations.
Metabolic flux analysis using ¹³C-labeled substrates in cell culture reveals altered carbon utilization patterns following clenbuterol exposure. Enhanced glycolytic flux and increased lactate production occur concomitantly with elevated oxygen consumption rates, indicating stimulated oxidative metabolism. These metabolic shifts correlate with AMPK activation and downstream transcriptional changes affecting metabolic enzyme expression.
Primary adipocyte isolation from rodent tissue provides physiologically relevant cell models for studying clenbuterol's metabolic effects. Lipolysis assays measuring glycerol release demonstrate dose-dependent responses with EC50 values of 10-100 nM. Time-course studies reveal biphasic responses, with initial PKA-mediated effects followed by sustained AMPK-dependent changes in gene expression.
C2C12 myoblast and myotube cultures serve as established models for investigating clenbuterol's effects on muscle metabolism. Glucose uptake assays using 2-deoxy-[³H]-glucose show enhanced glucose utilization following beta-2 AR activation. Mitochondrial biogenesis markers, including PGC-1α and cytochrome c oxidase subunit expression, increase in response to chronic clenbuterol exposure through CREB-mediated transcriptional activation.
Primary hepatocyte cultures and HepG2 cell lines demonstrate clenbuterol's effects on hepatic glucose metabolism. Glucose production assays reveal inhibition of gluconeogenesis through AMPK-mediated phosphorylation of key enzymes including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Glycogen synthesis rates increase following acute exposure, measured through incorporation of [¹⁴C]-glucose into glycogen polymers.
Kinetic analysis of clenbuterol-beta-2 AR interactions reveals rapid association kinetics (kon = 10⁷ M⁻¹s⁻¹) and relatively slow dissociation rates (koff = 0.01-0.1 s⁻¹), resulting in high-affinity binding with residence times exceeding several minutes. Functional selectivity studies demonstrate preferential coupling to adenylyl cyclase over alternative G-protein pathways, with minimal beta-arrestin recruitment compared to other beta-agonists.
Clenbuterol represents a valuable research tool for investigating beta-2 adrenergic receptor pharmacology and metabolic pathway regulation in vitro. Its high receptor selectivity, potent cAMP signaling activation, and downstream AMPK pathway integration make it particularly useful for studying metabolic enzyme regulation and cellular energy homeostasis. The compound's well-characterized binding kinetics and functional responses across multiple cell model systems provide researchers with reliable experimental frameworks for mechanistic studies of adrenergic signaling and metabolic control pathways.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.